SEARCH

SEARCH BY CITATION

References

  • 1
    Perrillo RP, Kruger M, Sievers T, Lake JR. Post-transplantation: Emerging and future therapies. Semin Liver Dis 2000; 20(suppl 1):S13S17.
  • 2
    Rosen HR, Martin P. Hepatitis B and C in liver transplant recipients. Semin Liver Dis 2000; 20:465480. MEDLINE
  • 3
    Tipples G, Ma M, Fischer K, et al. Mutations in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vitro. Hepatology 1996; 24:714720. MEDLINE
  • 4
    Terrault N, Zhou S, McCory RW, et al. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. Hepatology 1998; 28:555559. MEDLINE
  • 5
    Ghany M, Ayola B, Villamil F, Gish R, et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998; 27:213218. MEDLINE
  • 6
    Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329:18421847. MEDLINE
  • 7
    Terrault NA. Hepatitis B virus and liver transplantation. In: LeeWM, GitlinN (eds). Clinics in liver disease, vol 3. Philadelphia: Saunders, 1999:389415.
  • 8
    Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: A concise review. Hepatology 2000; 32:11891195. MEDLINE
  • 9
    Celis E, Abraham KG, Miller RW. Modulation of the immunological response to hepatitis B virus by antibodies. Hepatology 1987; 7:763769.
  • 10
    Feray C, Zignego AL, Samuel D, Bismuth A, Reynes AM, Tiollais P, et al. Persistent hepatitis B virus infection of mononuclear blood cells without concomitant liver infection. The liver transplantation model. Transplantation 1990; 49:11551158. MEDLINE
  • 11
    Sanchez-Fueyo A, Rimola A, Grande L, Costa J, Mas A, Navasa M, et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 2000; 31:496501. MEDLINE
  • 12
    Tisone G, Torri E, Araco A, Anselmo A, Camplone C, Zazza S, et al. Failure of double-reinforced course of HBV vaccination in patients transplanted for HBV-related cirrhosis [abstract 943]. Am J Transplantation 2001; 1:373A.
  • 13
    Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341:12561263. MEDLINE
  • 14
    Perillo RP, Wright T, Rakela J, Levy G, Schiff E, Gish R, et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001; 33:424432. MEDLINE
  • 15
    Villeneuve J-P, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000; 31:207210. MEDLINE
  • 16
    Yao F, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol 2000; 33:329332. MEDLINE
  • 17
    Weissberg JI, Andres LL, Smith CI, et al. Survival in chronic hepatitis B. An analysis of 379 patients. Ann Intern Med 1984; 101:613616. MEDLINE
  • 18
    DeJongh FE, Janssen HLA, DeMan RA, et al. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992; 103:16301635. MEDLINE
  • 19
    Fontana RJ, Keeffe EB, Han S, Wright T, Davis GL, Lilly L, et al. Prevention of recurrent hepatitis B infection following liver transplantation: Experience in 112 North American patients [abstract 562]. Hepatology 1999; 30:301A.
  • 20
    Han S-H, Ofman J, Holt C, King K, Kunder G, Chen P, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000; 6:741748. MEDLINE
  • 21
    Rizzetto M, Marzano A. Posttransplantation prevention and treatment of recurrent hepatitis B. Liver Transpl 2000; 6(suppl):S47S51. MEDLINE
  • 22
    Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28:585589. MEDLINE
  • 23
    Malkan G, Cattral MS, Humar A, Al Asghar H, Greig P, Hemming AW, et al. Lamivudine for hepatitis B in liver transplantation. Transplantation 2000; 69:14031407. MEDLINE
  • 24
    Nery JR, Weppler D, Rodriguez M, Ruiz P, Schiff ER, Tzakis AG. Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation. Transplantation 1998; 65:16151621. MEDLINE
  • 25
    Fontana RJ, Hann HW, Wright T, Everson G, Baker A, Schiff ER, et al. A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation. Liver Transpl 2001; 7:504510. MEDLINE
  • 26
    Locarnini S. Diagnosis and management of escape variants of hepatitis B virus. In: Schiff's Update XIV in Hepatobiliary Diseases, March 26–28, 2001, Miami Beach, FL; pp 4649.
  • 27
    Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, Schinazi RF. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001; 33:751757. MEDLINE
  • 28
    Trautwein C, Schrem H, Tilmann HL, Kubicka S, Walker D, Boker KH, et al. Hepatitis B virus mutations in the pre-S genome before and after liver transplantation. Hepatology 1996; 24:482488. MEDLINE
  • 29
    Allen MI, Deslauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998; 27:16701677. MEDLINE
  • 30
    Locarnini S, Birch C. Antiviral chemotherapy for chronic hepatitis B infection: Lessons learned from treating HIV infected patients. J Hepatol 1999; 30:536550. MEDLINE
  • 31
    McCaughan GW, Spencer J, Koorey D, Bowden S, Barholomeus A, Littejohn M, et al. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: High resistance rate in treatment of recurrence but universal prevention if used as prophylaxis with very low-dose hepatitis B immune globulin. Liver Transpl Surg 1999; 5:512519. MEDLINE
  • 32
    Papatheodoris GV, Dimou E, Papadimitropoulos V. Course of virologic breakthroughs under lamivudine therapy in patients with precore mutant HBV related liver disease [abstract 1974]. Gastroenterology 2001; 120:385A.
  • 33
    Ben-Ari Z, Mor E, Shapira Z, Tur-Kaspa R. Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation. Liver Transpl 2001; 7:113117. MEDLINE
  • 34
    Perrillo RP, Rakela J, Dienstag J, Levy G, Martin P, Wright T, et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Hepatology 1999; 29:15811586. MEDLINE
  • 35
    Mutimer D, Dusheiko G, Barrett C, Grellier L, Ahmed M, Anschuetz G, et al. Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: Long-term followup. Transplantation 2000:70:809815. MEDLINE
  • 36
    Liaw Y-F, Chien R-N, Yeh C-T, et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30:567572. MEDLINE
  • 37
    Saab S, Kim M, Wright TL, Han SHB, Martin P, Busuttil RW. Successful orthotopic liver transplantation for lamivudine-associated YMDD mutant hepatitis B virus. Gastroenterology 2000; 119:13821384. MEDLINE
  • 37a
    Rosenau J, Bahr MJ, Tillmann HL, Trautwein C, Klempnauer J, Manns MP, Boker KHW. Lamivudine and low-dose hepatitis immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation—A possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 2001; 34:895902. MEDLINE
  • 38
    Wolters LMM, Honkoop P, de Man RA, Niestes HGM, Schalm SW. Famciclovir treatment in lamivudine resistant chronic hepatitis B [abstract]. J Hepatol 1998; 28:113A.
  • 39
    Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32:129134. MEDLINE
  • 40
    Nevens F, de Man R, Chua D, Gadano A, Bies M, Thomas N, et al. Effectiveness of low dose entecavir in treating recurrent viremia in chronic hepatitis B [abstract]. Hepatology 2000; 32:376A.
  • 41
    Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000—Summary of a workshop. Gastroenterology 2001; 120:18261853.
  • 42
    Fukumoto T, Berg T, Ku Y, Bechstein WO, et al. Viral dynamics of hepatitis C early after orthotopic liver transplantation: Evidence for rapid turnover of serum virions. Hepatology 1996; 24:13511354. MEDLINE
  • 43
    Forman LM, Lucey MR. Orthotopic liver transplantation for hepatitis C: Analysis of allograft survival using the UNOS database [abstract 82]. Am J Transplantation 2001; 1(suppl 1):S156A.
  • 44
    Gane EJ, Portmann BC, Naoumouv NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334:821827. MEDLINE
  • 45
    Berenguer M, et al. HCV-related fibrosis progression following liver transplantation: Increase in recent years. J Hepatol 2000; 32:673684. MEDLINE
  • 46
    Berenguer M, Prieto M, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32:852858. MEDLINE
  • 47
    Fattovich G, et al. Morbidity and mortality in compensated cirrhosis type C: A retrospective followup study of 384 patients. Gastroenterology 1997; 112:463472. MEDLINE
  • 48
    Keeffe EB. Liver transplantation: Current status and novel approaches to liver replacement. Gastroenterology 2001; 120:749762. MEDLINE
  • 49
    Chazouilleres O, Kim M, Combs C, Ferrell L, Baccheti P, et al. Quantitation of hepatitis C virus RNA in liver transplant recipients. Gastroenterology 1994; 106:994999. MEDLINE
  • 50
    Gretch DR, Bacchi CE, Corey L, dela Rosa C, Lesniewski RR, Kowdley K, et al. Persistent hepatitis C virus infection after liver transplantation: Clinical and virological features. Hepatology 1995; 22:19. MEDLINE
  • 51
    Gane EJ, Naoumov NV, Qian K-P, Mondelli MU, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996; 110:167177. MEDLINE
  • 52
    Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28:823830. MEDLINE
  • 53
    Trotter J, Schiano T, Wachs M, Kim-Schluger L, Bak T, Kugelmas M, et al. Hepatitis C recurs earlier and is more severe in living donor liver transplant recipients (submitted).
  • 54
    Zervos XA, Weppler D, Fragulidis GP, Torres MB, Nery JR, Khan MF, et al. Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation. Transplantation 1998; 65:10441046. MEDLINE
  • 55
    Wiesner RH, and the US FK506 Study Group. A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation. Transplantation 1998; 66:493499. MEDLINE
  • 56
    Charlton M, Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: Results of NIDDK Liver Transplantation Database. Liver Transpl Surg 1999; 5(suppl):S107S114. MEDLINE
  • 57
    Sheiner PA, Schwartz ME, Mor E, et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995; 21:3034. MEDLINE
  • 58
    Rosen HR, Martin P, Shackleton CR, Farmer DA, Holt C, Busuttil RW. Use of OKT3 associated with early and severe hepatitis C recurrence following liver transplantation. Am J Gastroenterol 1997; 92:14531456; comments, 1416–1417.
  • 59
    Rosen HR, Martin P. OKT3 and hepatitis C: Defining the risks. Transplantation 1997; 63:171172. MEDLINE
  • 60
    Rosen HR, Chou S, Gretch DR, et al. Cytomegalovirus viremia: Risk factor for allograft cirrhosis following liver transplantation for hepatitis C. Transplantation 1997; 64:721726. MEDLINE
  • 61
    Charlton M, Seaberg EC, Wiesner RH, Paya C, Everhart J, Zetterman R, et al. Increased mortality following CMV infection in patients transplanted for HCV: Results of the NIDDK Liver Transplantation Database [abstract]. Hepatology 1998; 4:345A.
  • 62
    Rosen HR, Hinrichs DJ, Gretch DR, Koziel MJ, Chou S, Houghton M, Bouwer HA. Association of multispecific CD4+ response to hepatitis C and severity of recurrence after liver transplantation. Gastroenterology 1999; 117:926932; comments, 1012–1014.
  • 63
    Miner C, Koziel MJ, He Q, Rosen HR. Intrahepatic and circulating T cells following liver transplantation for HCV: Evidence of compartmentalization. AASLD 2001 (oral presentation).
  • 64
    Zekry A, Bishop A, McCaughan GW. Intrahepatic cytokine expression associated with hepatitis C virus recurrence post liver transplantation for HCV infection [abstract 174]. Am J Transplantation 2001; 1(suppl):S179A.
  • 65
    Johnson LB, Edwards E, Rustgi VK, Plotkin JS, Kuo PC. Impact of donor hepatitis C infection on recipient outcome following liver transplantation in the hepatitis C positive recipient: An analysis of the UNOS data [abstract]. Hepatology 1998; 28:388A.
  • 66
    Vargas HE, Laskus T, Wang L-F, Lee R, Radkowski M, Dodson F, et al. Outcome of liver transplantation in hepatitis C virus-infected grafts. Gastroenterology 1999; 117:149155. MEDLINE
  • 67
    Rosen HR, Martin P. Hepatitis C infection in patients undergoing liver retransplantation. Transplantation 1998; 66:16121616. MEDLINE
  • 68
    Rosen HR. Retransplantation for hepatitis C: Implications of different policies. Liver Transpl 2000; 6:4146. MEDLINE
  • 69
    Gane EJ, Lo SK, Riordan SM, Portmann BC, Lau JYN, Naoumov NV, et al. A randomized study comparing ribavirin and interferon alpha monotherapy for hepatitis C recurrence after liver transplantation. Hepatology 1998; 27:14031407. MEDLINE
  • 70
    Sheiner P, Boros O, Klion FM, Thung SN, Schluger LK, Lau JY, et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology 1998; 28:831838. MEDLINE
  • 71
    Singh N, Gayowski T, Wannstedt C, Shakil O, Wagener M, Fung J, et al. Interferon-α for prophylaxis of recurrent hepatitis C in liver transplant recipients. Transplantation 1998; 65:8286. MEDLINE
  • 72
    Bizzolon T, Ahmed SN, Radenne S, et al. Long-term histological improvement and clearance of intrahepatic HCV RNA following sustained response to IFN-ribavirin combination therapy in liver transplanted patients with HCV recurrence. (submitted).
  • 73
    Gopal D, Rabkin JM, Berk B, Corless CL, Orloff SL, Rosen HR. Treatment of progressive HCV recurrence following liver transplantation with combination interferon and ribavirin therapy. Liver Transpl 2001; 7:181190. MEDLINE
  • 74
    Riely C, Ferenci P, Peck-Radosavljevic M, Vogel B, Voigt M, Marks IM, Pappas SC. Pegylated (40 kDa) interferon alfa-2A (Pegysus) in post-liver transplant recipients with established recurrent hepatitis C: A preliminary report [abstract 89]. Am J Transplantation 2001; 1(suppl 1):S158A.